Lack of Suitable Resources Limiting Ebola Diagnoses in West Africa
Poor logistics and low trained staff numbers are two of the greatest limitations to providing a sufficient molecular diagnostic capacity for Ebola in West Africa, where only 56% of cases are described as confirmed and the remaining cases are probable or suspected, according to an analyst with research and consulting firm GlobalData.
Andrew S. Thompson, Ph.D., GlobalData’s Senior Analyst covering in vitro diagnostics, states that if the number of diagnosed Ebola cases in West Africa increased to 10,000 per week, as recently predicted by the World Health Organization, local diagnostic laboratories would need to be capable of processing at least 3400 specimens per day collectively, to support the number of positive tests and repeat negative tests expected.
Thompson says: “While modern molecular diagnostic testing is the most sensitive and precise way to detect the Ebola virus, it is complex and expensive to perform. It is therefore extremely challenging to implement this technology in poorer regions of the world, where the healthcare infrastructure is inadequate, or even nonexistent.
“At present, there continue to be only a few established diagnostic facilities in West Africa, and while donor countries are increasingly providing mobile laboratory facilities, these can only slightly narrow the gap in the testing capacity.”
The analyst notes that while the shortage of trained staff can be filled by deploying skilled scientists from outside the region, poor logistics is a more difficult problem to solve, as the reagents used for testing require constant refrigeration during their movement through the supply chain.
Thompson continues: “One solution might be to introduce molecular diagnostics suitable for the African environment. These could include reagents that are not dependent upon refrigeration, as well as instruments that are low-cost, self-powered, simple to use, and can be implemented quickly on short notice by governments in the region.
“This approach would provide a more robust model for responding to sporadic emergencies than the current approach, which depends on coordinating a global response and typically lags behind the first occurrence of the outbreak.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance